19:35 , Sep 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Patient sample, cell culture and mouse studies suggest inhibiting HspD1 could help treat glioblastoma multiforme (GBM). In glioma and GBM patients, high tumor levels of HspD1 correlated with poor survival. In a...
08:00 , Jan 25, 2016 |  BC Week In Review  |  Clinical News

VTP-34072: Additional Phase II data

Top-line data from the monotherapy arm of the double-blind, German Phase II trial in overweight Type II diabetics showed that once-daily oral VTP-34072 missed the “predefined primary efficacy endpoint criteria” of the change in FPG...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Clinical News

VTP-34072: Phase II data

Top-line data from a double-blind, German Phase II trial in overweight Type II diabetics showed that once-daily oral VTP-34072 as an add-on to metformin background therapy missed Boehringer’s “predefined endpoint criteria” on the primary efficacy...
07:00 , Jul 13, 2015 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg7/10 clsAmgen Inc. (NASDAQ:AMGN)UBSMatthew RodenDowngradeNeutral (from buy)1%$154.10 Roden also lowered his target to $165 from $185 after removing brodalumab from his model. At the end of May, Amgen...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Company News

Corticrine, Actinogen deal

Actinogen acquired Corticrine, a spinout of Edinburgh BioQuarter, the commercialization arm of the College of Medicine and Veterinary Medicine of the University of Edinburgh. Under the agreement, Actinogen issued 125 million shares and raised...
07:00 , Oct 27, 2014 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 10/24 cls Galenica Ltd. (SIX:GALN) UBS Guillaume van Renterghem ...
02:25 , Sep 25, 2014 |  BC Extra  |  Financial News

Vitae prices IPO below range

Vitae Pharmaceuticals Inc. (NASDAQ:VTAE) was down $0.39 to $7.61 in its first day of trading Wednesday after raising $55 million through the sale of 6.9 million shares at $8 in an IPO on NASDAQ. The...
02:14 , Sep 9, 2014 |  BC Extra  |  Financial News

Vitae sets IPO terms

Vitae Pharmaceuticals Inc. (Fort Washington, Pa.) set the terms for its IPO on NASDAQ. The company plans to sell 5 million shares at $11-$13. At the $12 midpoint, Vitae would raise $60 million and be...
01:34 , Aug 14, 2014 |  BC Extra  |  Financial News

Vitae files for IPO

Vitae Pharmaceuticals Inc. (Fort Washington, Pa.) filed to raise up to $55 million in an IPO on NASDAQ underwritten by Stifel; BMO Capital Markets; JMP Securities; and Wedbush PacGrow. Vitae's lead compound, VTP-34072, is in...
07:00 , Jul 31, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

Benjamin Boettner, Associate Editor, and Chris Cain, Michael J. Haas and Kai-Jye Lou, Senior Writers  Quantitative boost for CSHL The Simons Foundation has donated $50 million to Cold Spring Harbor Laboratory to establish the Simons Center for...